There are a number of liquid biopsy tests that have been approved by FDA so far, such as the breakthrough device from the Foundation Medicine company, approved at 2018; the cobas EGFR mutation test v2, approved for NSCLC in 2017; myRisk, approved for breast cancer in 2014 [119,120,121]. This evidence concerns the gene EGFR and breast carcinoma.